TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans

The first small-molecule CCR5 antagonist, TAK-779, could not be developed as an anti-human immunodeficiency virus type (anti-HIV-1) agent because of its poor oral bioavailability. TAK-652 is an orally bioavailable TAK-779 derivative with potent anti-HIV-1 activity. TAK-652 inhibited the binding of R...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Baba, Masanori, Takashima, Katsunori, Miyake, Hiroshi, Kanzaki, Naoyuki, Teshima, Koichiro, Wang, Xin, Shiraishi, Mitsuru, Iizawa, Yuji
Format: Članak
Jezik:English
Izdano: American Society for Microbiology 2005
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1280155/
https://ncbi.nlm.nih.gov/pubmed/16251299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.11.4584-4591.2005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC1280155/
https://ncbi.nlm.nih.gov/pubmed/16251299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.11.4584-4591.2005

Similar Items